DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost CAR T-Cell power against lymphoma
Disease control OngoingThis early-phase trial tests whether adding the drug acalabrutinib to CAR T-cell therapy can improve treatment for certain B-cell lymphomas. Acalabrutinib blocks cancer growth pathways, while the CAR T-cells are engineered to attack lymphoma cells. The study involves 23 adults an…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to stop aggressive lymphoma in its tracks
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. The trial includes 363 people with aggressive lymphoma subtypes. Venetoclax targets a protein that helps cancer cells survive, while …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to extend remission in elderly lymphoma patients
Disease control OngoingThis study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New CAR-T therapy targets Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Engineered immune cells take on tough lymphoma
Disease control OngoingThis early-phase trial tests a new type of CAR T-cell therapy for adults with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The study aims to find the safest dose a…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
CAR-T therapy takes on High-Risk lymphoma as First-Line treatment
Disease control OngoingThis phase 3 trial is testing whether a single infusion of a patient's own genetically modified immune cells (CAR-T therapy, called Yescarta) works better than standard chemotherapy plus antibody treatment as the very first therapy for people with high-risk large B-cell lymphoma.…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill plus chemo aims to beat High-Risk lymphoma
Disease control OngoingThis phase 3 study tests whether adding the experimental drug golcadomide to standard R-CHOP chemotherapy helps people with untreated high-risk large B-cell lymphoma live longer without their cancer worsening. About 850 adults will be randomly assigned to get either golcadomide o…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells primed with decitabine show promise for tough lymphoma
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with B-cell Non-Hodgkin's lymphoma that has returned or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in the lab to target two proteins (CD19 and CD20) on canc…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Han weidong • Aim: Disease control
Last updated Jun 26, 2026 19:07 UTC
-
Withdrawn trial: could glofitamab stop hidden lymphoma cells?
Disease control TerminatedThis study aimed to see if the drug glofitamab could prevent large B-cell lymphoma from coming back in patients who had achieved complete remission but still had minimal residual disease (MRD) after standard chemotherapy. The trial was withdrawn before any patients were enrolled,…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 18:44 UTC
-
Nanochip could spot lymphoma relapse early
Knowledge-focused OngoingThis pilot study is testing a nanochip (ILN biochip) to see if it can monitor how well treatment is working and detect relapse in people with diffuse large B-cell lymphoma. About 73 patients will provide blood samples for the chip to analyze genetic markers. The goal is to find o…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC